%0 Journal Article %A TAKURO OKADA %A TAKASHI MATSUKI %A CHIHIRO FUSHIMI %A ISAKU OKAMOTO %A HIROKI SATO %A TAKAHITO KONDO %A KUNIHIKO TOKASHIKI %A TATSUYA ITO %A TATSUO MASUBUCHI %A YUICHIRO TADA %A KOUKI MIURA %A KENJI HANYU %A GO OMURA %A HIDEKI TAKAHASHI %A TAKU YAMASHITA %A NOBUHIKO ORIDATE %A KIYOAKI TSUKAHARA %T Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma %D 2022 %R 10.21873/anticanres.15996 %J Anticancer Research %P 4907-4912 %V 42 %N 10 %X Background/Aim: Nivolumab has antitumor efficacy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who relapse within 6 months after platinum-based therapy; however, the efficacy of nivolumab for platinum-sensitive R/M HNSCC has not been shown. Therefore, this study compared the efficacy and safety of nivolumab for platinum-refractory and platinum-sensitive R/M HNSCC. Patients and Methods: This was a retrospective study of patients who received nivolumab for R/M HNSCC who had been previously treated with platinum-based anticancer drugs. Patients were divided into a platinum-sensitive and a platinum-refractory group, and progression-free survival (PFS), overall survival (OS), the overall response rate (ORR) [complete response (CR) + partial response (PR)], the disease control rate (DCR) (CR + PR + stable disease), and the incidence of immune-related adverse events (irAEs) were compared between the two groups. Results: We included 88 patients with squamous cell carcinoma: 60 with platinum-refractory disease and 28 with platinum-sensitive disease. The median PFS in the platinum-refractory and platinum-sensitive groups were 2.7 months and 5.3 months, respectively (p=0.03), and the median OS were 8.8 months and 17.1 months, respectively (p=0.06). There were no significant differences in the ORR, DCR, or incidence of irAEs between the two groups (p>0.99, p=0.11, and p>0.99, respectively). Conclusion: Nivolumab is a safe and effective treatment for platinum-sensitive R/M HNSCC. %U https://ar.iiarjournals.org/content/anticanres/42/10/4907.full.pdf